GENE ONLINE|News &
Opinion
Blog

2025-10-09|

Deep Brain Stimulation Targets Left Thalamus to Address Developmental Stuttering

by Mark Chiang
Share To

Researchers from Goethe University Frankfurt and Münster have introduced a new approach to addressing persistent developmental stuttering through the use of deep brain stimulation (DBS). The technique targets the left thalamus, a region in the brain associated with speech processing. Stuttering, historically viewed as a condition rooted solely in psychological factors, is now increasingly understood as a complex disorder involving neurological components. This study marks a significant step in exploring potential treatments for individuals affected by this speech flow disorder.

The research highlights the application of DBS, often referred to as a “brain pacemaker,” which delivers electrical impulses to specific areas of the brain. By focusing on the left thalamus, scientists aim to regulate neural activity linked to speech production and fluency. While stuttering has traditionally been approached through behavioral therapies and psychological interventions, this method underscores its biological underpinnings. The findings suggest that targeting neurological pathways may offer new avenues for managing stuttering symptoms effectively. Further studies are expected to evaluate the long-term efficacy and safety of this innovative treatment strategy.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 9, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
LATEST
Shine Spect USA Updates Clinical and Safety Guidelines for Xenon Xe-133 Gas
2026-09-11
Amorepacific Updates Hera Black Cushion Ingredient Disclosures for Ten Foundation Shades
2026-09-11
AvKARE Updates Prescribing Information for Etonogestrel and Ethinyl Estradiol Vaginal Ring
2026-09-11
Record Investor Attendance at NLS Days 2026 Drives Nordic Life Science Dealmaking
2026-09-11
Disc Medicine and Silence Therapeutics Develop Polycythemia Vera Treatments to Compete With Takeda and Protagonist
2026-09-11
Leucine Supplementation Linked to Reduced Lymphoid Malignancy Growth and Improved Survival in Study
2026-09-11
Actavis Pharma Updates Ciclopirox Shampoo Prescribing Information as of September 10, 2026
2026-09-10
Scroll to Top